Hepatocellular | Nano Publications

2020 – ESTRO – NBTXR3 for the Treatment of Advanced Liver Cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

The use of stereotactic body radiotherapy (SBRT) for the local control of unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) is well tolerated but limited by the need to preserve liver function. Increasing energy deposit within the tumor without increasing toxicity in healthy tissues remains a major challenge in radiation oncology. NBTXR3 (hafnium oxide nanoparticles), a first-in-class radioenhancer when activated by RT augments energy dose deposit within tumor cells, increasing tumor cell death compared to RT alone, while sparing healthy tissues. […]

2019 – Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis

Clinical Data NBTXR3, Congress Abstracts, Liver

Treatment of hepatocellular carcinoma (HCC) and liver metastasis (mets) is challenging due to presence of underlying disease, e.g. cirrhosis. Stereotactic body radiation therapy (SBRT) is a well-tolerated alternative for inoperable patients (pts), yet maximal dose to the tumor is limited by potential toxicity to surrounding healthy tissues. […]

2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial

Clinical Data NBTXR3, Congress Abstracts, Liver, NO-RIGHTS

The medical community faces important challenges to treat liver cancer because of underlying disease. Reduction of healthy tissue irradiation while at the same time increasing energy dose deposit within tumor cells still constitutes a challenge in radiation oncology. NBTXR3, hafnium oxide nanoparticles, increase energy deposit inside tumor cells only when activated by ionizing radiation such as stereotactic body radiotherapy (SBRT) and thus increase tumor cell death compared to radiation alone. […]

2019 – ASTRO – NBTXR3 for the treatment liver cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

2019 – ESMO WGI – NBTXR3 in unresectable liver cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

The treatment of liver cancers is challenging in part due to the presence of underlying liver diseases. In patients unsuitable for surgery, interventional radiation oncology approaches, i.e. minimally invasive image guided therapeutic procedures, offer new treatment opportunities and can achieve good local control. NBTXR3, hafnium oxide nanoparticles, administered via intratumoral injection, increases energy deposit inside tumor cells only when activated by ionizing radiation such as stereotactic body radiotherapy (SBRT) and thus increase tumor cell death compared to radiation alone. […]

2019 – ASCO – NBTXR3 in Liver Cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

Hafnium oxide nanoparticles, NBTXR3, increase the effect of radiotherapy (RT) by enhancing local energy dose deposit within tumor cells, resulting in increased cell death compared to the same dose of RT alone. NBTXR3 efficacy was demonstrated in a phase II/III study in soft tissue sarcoma (NCT02379845) and is currently evaluated in other solid tumors including liver cancers. The use of this radio enhancer is particularly relevant in liver cancer management, a difficult to treat heterogenous population, due to the presence of underlying liver dysfunction. […]

2019 – ESTRO – NBTXR3 activated by SBRT in liver cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

Patients with hepatocellular carcinoma (HCC) and liver metastasis (mets) present with a wide range of underlying liver dysfunctions and concomitant malignancies. Stereotactic body radiation therapy (SBRT) is well-tolerated and a valuable alternative for patients who are not eligible for invasive procedures. Yet, like all radiation therapy (RT) techniques, the energy dose deposit to tumor cells is limited by the surrounding healthy tissues. […]

2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis

Clinical Data NBTXR3, Congress Abstracts, Liver

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]